NERV: the cash flow

MyFinsight

For the year ending 2025-12-31, NERV had $60,939,805 increase in cash & cash equivalents over the period.

Cash Flow	2025-12-31
Total expenses	15,102,970
Loss from operations	-15,102,970
Foreign exchange losses	-56,555
Investment income	948,122
Loss on issuance of convertible preferred stock and warrants	321,499,041
Warrant issuance cost	3,102,649
Changes in fair value of the warrant liability	-45,389,916
Net (loss) income	-293,423,177
Depreciation and amortization	5,442
Stock-based compensation expense	1,327,372
Loss on issuance of convertible preferred stock and warrants	321,499,041
Warrant issuance cost	3,102,649
Changes in fair value of the warrant liability	-45,389,916
Prepaid expenses and other current assets	-109,219
Accounts payable	-1,059,012
Accrued expenses and other current liabilities	317,446
Net cash used in operating activities	-13,510,936
Net cash provided by investing activities	0
Proceeds from sales of common stock and warrants in private placement	80,000,000
Costs paid in connection with private placement	5,393,311
Payment of deferred offering costs	155,948
Net cash provided by (used in) financing activities	74,450,741
Net increase (decrease) in cash, cash equivalents and restricted cash	60,939,805
Beginning of period	21,462,008
End of period	82,401,813

Unit: Dollar.